{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T18:35:27Z","timestamp":1794681327880,"version":"4.9.1"},"reference-count":254,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Dis Primers"],"DOI":"10.1038\/s41572-025-00653-y","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T07:03:44Z","timestamp":1758783824000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Lupus nephritis"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-5395","authenticated-orcid":false,"given":"Ioannis","family":"Parodis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5639-0210","authenticated-orcid":false,"given":"Brad H.","family":"Rovin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2238-0975","authenticated-orcid":false,"given":"Maria G.","family":"Tektonidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-2956","authenticated-orcid":false,"given":"Hans-Joachim","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1609-3857","authenticated-orcid":false,"given":"Ana","family":"Malvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3696-1228","authenticated-orcid":false,"given":"Chi Chiu","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"653_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.39","volume":"2","author":"A Kaul","year":"2016","unstructured":"Kaul, A. et al. Systemic lupus erythematosus. Nat. Rev. Dis. Primers\u00a02, 16039 (2016).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"653_CR2","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","volume":"403","author":"A Hoi","year":"2024","unstructured":"Hoi, A., Igel, T., Mok, C. C. & Arnaud, L. Systemic lupus erythematosus. Lancet 403, 2326\u20132338 (2024).","journal-title":"Lancet"},{"key":"653_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","volume":"6","author":"HJ Anders","year":"2020","unstructured":"Anders, H. J. et al. Lupus nephritis. Nat. Rev. Dis. Primers\u00a06, 7 (2020).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"653_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis, A. et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann. Rheum. Dis. 83, 15\u201329 (2024). This work provides updated, evidence-based guidelines for the management of systemic lupus erythematosus, including LN, developed by an international multidisciplinary task force under the EULAR.","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR5","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical practice guideline for the management of LUPUS NEPHRITIS. Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2023.09.002 (2024). This guideline offers comprehensive recommendations for the diagnosis, treatment and long-term management of LN, developed by the Kidney Disease: Improving Global Outcomes initiative based on the latest clinical and research advances.","DOI":"10.1016\/j.kint.2023.09.002"},{"key":"653_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.kint.2023.09.001","volume":"105","author":"BH Rovin","year":"2024","unstructured":"Rovin, B. H. et al. Executive summary of the KDIGO 2024 clinical practice guideline for the management of lupus nephritis. Kidney Int. 105, 31\u201334 (2024).","journal-title":"Kidney Int."},{"key":"653_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/art.43212","author":"LR Sammaritano","year":"2025","unstructured":"Sammaritano, L. R. et al. 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.43212 (2025).","journal-title":"Arthritis Rheumatol."},{"key":"653_CR8","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.kint.2016.03.042","volume":"90","author":"PJ Hoover","year":"2016","unstructured":"Hoover, P. J. & Costenbader, K. H. Insights into the epidemiology and management of lupus nephritis from the US rheumatologist\u2019s perspective. Kidney Int. 90, 487\u2013492 (2016).","journal-title":"Kidney Int."},{"key":"653_CR9","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1016\/j.ekir.2024.09.028","volume":"9","author":"DYH Yap","year":"2024","unstructured":"Yap, D. Y. H. et al. Long-term kidney outcome of lupus nephritis by renal response status. Kidney Int. Rep. 9, 3532\u20133541 (2024).","journal-title":"Kidney Int. Rep."},{"key":"653_CR10","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1093\/rheumatology\/keaa491","volume":"60","author":"E Gisca","year":"2021","unstructured":"Gisca, E., Duarte, L., Farinha, F. & Isenberg, D. A. Assessing outcomes in a lupus nephritis cohort over a 40-year period. Rheumatology 60, 1814\u20131822 (2021).","journal-title":"Rheumatology"},{"key":"653_CR11","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1002\/acr.25002","volume":"75","author":"EA Smitherman","year":"2023","unstructured":"Smitherman, E. A. et al. Childhood-onset lupus nephritis in the Childhood Arthritis and Rheumatology Research Alliance registry: short-term kidney status and variation in care. Arthritis Care Res. 75, 1553\u20131562 (2023).","journal-title":"Arthritis Care Res."},{"key":"653_CR12","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1177\/09612033211028658","volume":"30","author":"KM Vazzana","year":"2021","unstructured":"Vazzana, K. M. et al. Principles of pediatric lupus nephritis in a prospective contemporary multi-center cohort. Lupus 30, 1660\u20131670 (2021).","journal-title":"Lupus"},{"key":"653_CR13","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s00467-020-04686-1","volume":"36","author":"L Oni","year":"2021","unstructured":"Oni, L., Wright, R. D., Marks, S., Beresford, M. W. & Tullus, K. Kidney outcomes for children with lupus nephritis. Pediatr. Nephrol. 36, 1377\u20131385 (2021).","journal-title":"Pediatr. Nephrol."},{"key":"653_CR14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","volume":"55","author":"JG Hanly","year":"2016","unstructured":"Hanly, J. G. et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology 55, 252\u2013262 (2016).","journal-title":"Rheumatology"},{"key":"653_CR15","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/art.37795","volume":"65","author":"CH Feldman","year":"2013","unstructured":"Feldman, C. H. et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with medicaid coverage, 2000-2004. Arthritis Rheum. 65, 753\u2013763 (2013).","journal-title":"Arthritis Rheum."},{"key":"653_CR16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/art.42375","volume":"75","author":"M Hocao\u01e7lu","year":"2023","unstructured":"Hocao\u01e7lu, M. et al. Incidence, prevalence, and mortality of lupus nephritis: a population-based study over four decades using the lupus midwest network. Arthritis Rheumatol. 75, 567\u2013573 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"653_CR17","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3899\/jrheum.151221","volume":"43","author":"ML Hermansen","year":"2016","unstructured":"Hermansen, M. L., Lindhardsen, J., Torp-Pedersen, C., Faurschou, M. & Jacobsen, S. Incidence of systemic lupus erythematosus and lupus nephritis in Denmark: a nationwide cohort study. J. Rheumatol. 43, 1335\u20131339 (2016).","journal-title":"J. Rheumatol."},{"key":"653_CR18","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/art.22375","volume":"56","author":"RM Andrade","year":"2007","unstructured":"Andrade, R. M. et al. Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort. Arthritis Rheum. 56, 622\u2013630 (2007).","journal-title":"Arthritis Rheum."},{"key":"653_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/art.40392","volume":"70","author":"CH Feldman","year":"2018","unstructured":"Feldman, C. H., Broder, A., Guan, H., Yazdany, J. & Costenbader, K. H. Sex differences in health care utilization, end-stage renal disease, and mortality among Medicaid beneficiaries with incident lupus nephritis. Arthritis Rheumatol. 70, 417\u2013426 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"653_CR20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1053\/j.ajkd.2019.10.017","volume":"76","author":"SV Parikh","year":"2020","unstructured":"Parikh, S. V., Almaani, S., Brodsky, S. & Rovin, B. H. Update on lupus nephritis: core curriculum 2020. Am. J. Kidney Dis. 76, 265\u2013281 (2020).","journal-title":"Am. J. Kidney Dis."},{"key":"653_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.15079","volume":"27","author":"JC Nossent","year":"2024","unstructured":"Nossent, J. C., Keen, H. I., Preen, D. B. & Inderjeeth, C. A. Population-wide long-term study of incidence, renal failure, and mortality rates for lupus nephritis. Int. J. Rheum. Dis. 27, e15079 (2024).","journal-title":"Int. J. Rheum. Dis."},{"key":"653_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2215\/CJN.02350314","volume":"10","author":"DJ Sexton","year":"2015","unstructured":"Sexton, D. J. et al. ESRD from lupus nephritis in the United States, 1995\u20132010. Clin. J. Am. Soc. Nephrol. 10, 251\u2013259 (2015).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"653_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrneph.2015.33","volume":"11","author":"C Mohan","year":"2015","unstructured":"Mohan, C. & Putterman, C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat. Rev. Nephrol. 11, 329\u2013341 (2015).","journal-title":"Nat. Rev. Nephrol."},{"key":"653_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2023.101894","volume":"37","author":"I Parodis","year":"2023","unstructured":"Parodis, I., Lanata, C., Nikolopoulos, D., Blazer, A. & Yazdany, J. Reframing health disparities in SLE: a critical reassessment of racial and ethnic differences in lupus disease outcomes. Best Pract. Res. Clin. Rheumatol. 37, 101894 (2023).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"653_CR25","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/art.38220","volume":"66","author":"BI Freedman","year":"2014","unstructured":"Freedman, B. I. et al. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol. 66, 390\u2013396 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"653_CR26","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/art.39594","volume":"68","author":"MG Tektonidou","year":"2016","unstructured":"Tektonidou, M. G., Dasgupta, A. & Ward, M. M. Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and bayesian meta-analysis. Arthritis Rheumatol. 68, 1432\u20131441 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"653_CR27","doi-asserted-by":"publisher","unstructured":"Kapsia, E. et al. Predictors of early response, flares, and long-term adverse renal outcomes in proliferative lupus nephritis: a 100-month median follow-up of an inception cohort. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm11175017 (2022).","DOI":"10.3390\/jcm11175017"},{"key":"653_CR28","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1053\/j.ajkd.2015.04.011","volume":"66","author":"R Nee","year":"2015","unstructured":"Nee, R. et al. Survival disparity of African American versus non-African American patients with ESRD due to SLE. Am. J. Kidney Dis. 66, 630\u2013637 (2015).","journal-title":"Am. J. Kidney Dis."},{"key":"653_CR29","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/acr.22173","volume":"66","author":"M Yurkovich","year":"2014","unstructured":"Yurkovich, M., Vostretsova, K., Chen, W. & Avi\u00f1a-Zubieta, J. A. Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res. 66, 608\u2013616 (2014).","journal-title":"Arthritis Care Res."},{"key":"653_CR30","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1136\/annrheumdis-2017-211663","volume":"76","author":"MG Tektonidou","year":"2017","unstructured":"Tektonidou, M. G., Lewandowski, L. B., Hu, J., Dasgupta, A. & Ward, M. M. Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Ann. Rheum. Dis. 76, 2009\u20132016 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR31","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1177\/09612033241257134","volume":"33","author":"YH Lee","year":"2024","unstructured":"Lee, Y. H. & Song, G. G. Mortality in patients with systemic lupus erythematosus: a meta-analysis of overall and cause-specific effects. Lupus 33, 929\u2013937 (2024).","journal-title":"Lupus"},{"key":"653_CR32","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1136\/ard-2022-222839","volume":"82","author":"A Lorenzo-Vizcaya","year":"2023","unstructured":"Lorenzo-Vizcaya, A. & Isenberg, D. A. Clinical trials in systemic lupus erythematosus: the dilemma \u2014 why have phase III trials failed to confirm the promising results of phase II trials? Ann. Rheum. Dis. 82, 169\u2013174 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR33","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41581-023-00732-x","volume":"19","author":"CG Vinuesa","year":"2023","unstructured":"Vinuesa, C. G., Shen, N. & Ware, T. Genetics of SLE: mechanistic insights from monogenic disease and disease-associated variants. Nat. Rev. Nephrol. 19, 558\u2013572 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"653_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00281-021-00900-w","volume":"44","author":"E Ha","year":"2022","unstructured":"Ha, E., Bae, S. C. & Kim, K. Recent advances in understanding the genetic basis of systemic lupus erythematosus. Semin. Immunopathol. 44, 29\u201346 (2022).","journal-title":"Semin. Immunopathol."},{"key":"653_CR35","doi-asserted-by":"crossref","unstructured":"Lennard Richard, M. L. & Tsao, B. P. in Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects (ed. Tsokos, G. C.) 11, 85\u201396 (Academic, 2020).","DOI":"10.1016\/B978-0-12-814551-7.00011-8"},{"key":"653_CR36","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1806891","volume":"380","author":"EE Groopman","year":"2019","unstructured":"Groopman, E. E. et al. Diagnostic utility of exome sequencing for kidney disease. N. Engl. J. Med. 380, 142\u2013151 (2019).","journal-title":"N. Engl. J. Med."},{"key":"653_CR37","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1080\/1744666X.2023.2240959","volume":"19","author":"S Guga","year":"2023","unstructured":"Guga, S., Wang, Y., Graham, D. C. & Vyse, T. J. A review of genetic risk in systemic lupus erythematosus. Expert Rev. Clin. Immunol. 19, 1247\u20131258 (2023).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"653_CR38","doi-asserted-by":"publisher","first-page":"i15","DOI":"10.1093\/rheumatology\/keac695","volume":"62","author":"K Demkova","year":"2023","unstructured":"Demkova, K., Morris, D. L. & Vyse, T. J. Genetics of SLE: does this explain susceptibility and severity across racial groups? Rheumatology 62, i15\u2013i21 (2023).","journal-title":"Rheumatology"},{"key":"653_CR39","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/joim.13448","volume":"291","author":"JMP Woo","year":"2022","unstructured":"Woo, J. M. P., Parks, C. G., Jacobsen, S., Costenbader, K. H. & Bernatsky, S. The role of environmental exposures and gene-environment interactions in the etiology of systemic lupus erythematous. J. Intern. Med. 291, 755\u2013778 (2022).","journal-title":"J. Intern. Med."},{"key":"653_CR40","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/annrheumdis-2017-211675","volume":"77","author":"M Barbhaiya","year":"2018","unstructured":"Barbhaiya, M. et al. Cigarette smoking and the risk of systemic lupus erythematosus, overall and by anti-double stranded DNA antibody subtype, in the Nurses\u2019 Health Study cohorts. Ann. Rheum. Dis. 77, 196\u2013202 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR41","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1136\/annrheumdis-2019-215361","volume":"78","author":"NR Jog","year":"2019","unstructured":"Jog, N. R. et al. Association of Epstein\u2013Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals. Ann. Rheum. Dis. 78, 1235\u20131241 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR42","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1002\/art.41414","volume":"72","author":"J Cui","year":"2020","unstructured":"Cui, J. et al. Interactions between genome-wide genetic factors and smoking influencing risk of systemic lupus erythematosus. Arthritis Rheumatol. 72, 1863\u20131871 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"653_CR43","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41588-018-0102-3","volume":"50","author":"JB Harley","year":"2018","unstructured":"Harley, J. B. et al. Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nat. Genet. 50, 699\u2013707 (2018).","journal-title":"Nat. Genet."},{"key":"653_CR44","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41525-024-00420-0","volume":"9","author":"O Castellini-P\u00e9rez","year":"2024","unstructured":"Castellini-P\u00e9rez, O. et al. Molecular subtypes explain lupus epigenomic heterogeneity unveiling new regulatory genetic risk variants. npj Genom. Med. 9, 38 (2024).","journal-title":"npj Genom. Med."},{"key":"653_CR45","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41581-023-00722-z","volume":"19","author":"C Mohan","year":"2023","unstructured":"Mohan, C., Zhang, T. & Putterman, C. Pathogenic cellular and molecular mediators in lupus nephritis. Nat. Rev. Nephrol. 19, 491\u2013508 (2023). This review provides a detailed overview of the key cellular and molecular pathways driving LN pathogenesis, highlighting potential therapeutic targets for future intervention.","journal-title":"Nat. Rev. Nephrol."},{"key":"653_CR46","doi-asserted-by":"publisher","unstructured":"Abraham, R. et al. Specific in situ inflammatory states associate with progression to renal failure in lupus nephritis. J. Clin. Invest. https:\/\/doi.org\/10.1172\/jci155350 (2022).","DOI":"10.1172\/jci155350"},{"key":"653_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.103025","volume":"136","author":"J Lindblom","year":"2023","unstructured":"Lindblom, J. et al. Distinct gene dysregulation patterns herald precision medicine potentiality in systemic lupus erythematosus. J. Autoimmun. 136, 103025 (2023).","journal-title":"J. Autoimmun."},{"key":"653_CR48","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1136\/ard-2023-224795","volume":"83","author":"I Parodis","year":"2024","unstructured":"Parodis, I. et al. Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort. Ann. Rheum. Dis. 83, 889\u2013900 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1217147","volume":"10","author":"D Nikolopoulos","year":"2023","unstructured":"Nikolopoulos, D. & Parodis, I. Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition. Front. Med. 10, 1217147 (2023).","journal-title":"Front. Med."},{"key":"653_CR50","doi-asserted-by":"publisher","unstructured":"Kale, A., Shelke, V., Lei, Y., Gaikwad, A. B. & Anders, H. J. Voclosporin: unique chemistry, pharmacology and toxicity profile, and possible options for implementation into the management of lupus nephritis. Cells https:\/\/doi.org\/10.3390\/cells12202440 (2023).","DOI":"10.3390\/cells12202440"},{"key":"653_CR51","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1016\/j.ymthe.2022.04.024","volume":"30","author":"L Li","year":"2022","unstructured":"Li, L. et al. Targeting tissue-resident memory CD8+ T cells in the kidney is a potential therapeutic strategy to ameliorate podocyte injury and glomerulosclerosis. Mol. Ther. 30, 2746\u20132759 (2022).","journal-title":"Mol. Ther."},{"key":"653_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102424","volume":"109","author":"M Zhou","year":"2020","unstructured":"Zhou, M. et al. JAK\/STAT signaling controls the fate of CD8+CD103+ tissue-resident memory T cell in lupus nephritis. J. Autoimmun. 109, 102424 (2020).","journal-title":"J. Autoimmun."},{"key":"653_CR53","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.4049\/jimmunol.1301859","volume":"192","author":"H Kato","year":"2014","unstructured":"Kato, H. & Perl, A. Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4\u2212CD8\u2212 double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus. J. Immunol. 192, 4134\u20134144 (2014).","journal-title":"J. Immunol."},{"key":"653_CR54","doi-asserted-by":"publisher","first-page":"8761","DOI":"10.4049\/jimmunol.181.12.8761","volume":"181","author":"JC Crisp\u00edn","year":"2008","unstructured":"Crisp\u00edn, J. C. et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J. Immunol. 181, 8761\u20138766 (2008).","journal-title":"J. Immunol."},{"key":"653_CR55","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.cell.2016.03.008","volume":"165","author":"R Banchereau","year":"2016","unstructured":"Banchereau, R. et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 165, 551\u2013565 (2016).","journal-title":"Cell"},{"key":"653_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196117","volume":"13","author":"JE Wither","year":"2018","unstructured":"Wither, J. E. et al. Identification of a neutrophil-related gene expression signature that is enriched in adult systemic lupus erythematosus patients with active nephritis: clinical\/pathologic associations and etiologic mechanisms. PLoS ONE 13, e0196117 (2018).","journal-title":"PLoS ONE"},{"key":"653_CR57","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.ekir.2024.03.014","volume":"9","author":"I Parodis","year":"2024","unstructured":"Parodis, I. et al. Interferon and B-cell signatures inform precision medicine in lupus nephritis. Kidney Int. Rep. 9, 1817\u20131835 (2024).","journal-title":"Kidney Int. Rep."},{"key":"653_CR58","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1002\/art.41395","volume":"72","author":"SH Tay","year":"2020","unstructured":"Tay, S. H., Celhar, T. & Fairhurst, A. M. Low-density neutrophils in systemic lupus erythematosus. Arthritis Rheumatol. 72, 1587\u20131595 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"653_CR59","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1172\/JCI125116","volume":"129","author":"J Kuriakose","year":"2019","unstructured":"Kuriakose, J. et al. Patrolling monocytes promote the pathogenesis of early lupus-like glomerulonephritis. J. Clin. Invest. 129, 2251\u20132265 (2019).","journal-title":"J. Clin. Invest."},{"key":"653_CR60","doi-asserted-by":"publisher","unstructured":"Richoz, N. et al. Distinct pathogenic roles for resident and monocyte-derived macrophages in lupus nephritis. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.159751 (2022).","DOI":"10.1172\/jci.insight.159751"},{"key":"653_CR61","doi-asserted-by":"publisher","unstructured":"Hoover, P. J. et al. Intrarenal myeloid subsets associated with kidney injury are comparable in mice and patients with lupus nephritis. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.06.24.546409 (2023).","DOI":"10.1101\/2023.06.24.546409"},{"key":"653_CR62","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/s41586-024-07907-x","volume":"634","author":"SI Biniaris-Georgallis","year":"2024","unstructured":"Biniaris-Georgallis, S. I. et al. Amplification of autoimmune organ damage by NKp46-activated ILC1s. Nature 634, 952\u2013960 (2024).","journal-title":"Nature"},{"key":"653_CR63","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/BOR.0000000000000994","volume":"36","author":"R Appalaneni","year":"2024","unstructured":"Appalaneni, R., Achanta, N. & Mohan, C. Chimeric antigen receptor T-cell therapy in rheumatology: B-cell depletion 2.0. Curr. Opin. Rheumatol. 36, 126\u2013133 (2024).","journal-title":"Curr. Opin. Rheumatol."},{"key":"653_CR64","doi-asserted-by":"publisher","unstructured":"Parodis, I., Long, X., Karlsson, M. C. I. & Huang, X. B cell tolerance and targeted therapies in SLE. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm12196268 (2023).","DOI":"10.3390\/jcm12196268"},{"key":"653_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1126421","volume":"14","author":"Z Zhang","year":"2023","unstructured":"Zhang, Z., Xu, Q. & Huang, L. B cell depletion therapies in autoimmune diseases: monoclonal antibodies or chimeric antigen receptor-based therapy? Front. Immunol. 14, 1126421 (2023).","journal-title":"Front. Immunol."},{"key":"653_CR66","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.4049\/jimmunol.1001983","volume":"186","author":"A Chang","year":"2011","unstructured":"Chang, A. et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J. Immunol. 186, 1849\u20131860 (2011).","journal-title":"J. Immunol."},{"key":"653_CR67","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature13835","volume":"518","author":"KK Farh","year":"2015","unstructured":"Farh, K. K. et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518, 337\u2013343 (2015).","journal-title":"Nature"},{"key":"653_CR68","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1146\/annurev-immunol-092419-031130","volume":"38","author":"MP Cancro","year":"2020","unstructured":"Cancro, M. P. Age-associated B cells. Annu. Rev. Immunol. 38, 315\u2013340 (2020).","journal-title":"Annu. Rev. Immunol."},{"key":"653_CR69","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.immuni.2018.08.015","volume":"49","author":"SA Jenks","year":"2018","unstructured":"Jenks, S. A. et al. Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity 49, 725\u2013739.e726 (2018).","journal-title":"Immunity"},{"key":"653_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03750-7","volume":"9","author":"S Wang","year":"2018","unstructured":"Wang, S. et al. IL-21 drives expansion and plasma cell differentiation of autoreactive CD11chiT-bet+ B cells in SLE. Nat. Commun. 9, 1758 (2018).","journal-title":"Nat. Commun."},{"key":"653_CR71","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fmed.2020.00085","volume":"7","author":"X You","year":"2020","unstructured":"You, X. et al. Double negative B cell is associated with renal impairment in systemic lupus erythematosus and acts as a marker for nephritis remission. Front. Med. 7, 85 (2020).","journal-title":"Front. Med."},{"key":"653_CR72","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1136\/annrheumdis-2019-215039","volume":"78","author":"C Wu","year":"2019","unstructured":"Wu, C. et al. Lupus-associated atypical memory B cells are mTORC1-hyperactivated and functionally dysregulated. Ann. Rheum. Dis. 78, 1090\u20131100 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR73","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41590-019-0398-x","volume":"20","author":"A Arazi","year":"2019","unstructured":"Arazi, A. et al. The immune cell landscape in kidneys of patients with lupus nephritis. Nat. Immunol. 20, 902\u2013914 (2019).","journal-title":"Nat. Immunol."},{"key":"653_CR74","first-page":"1495","volume":"30","author":"M Mannik","year":"2003","unstructured":"Mannik, M., Merrill, C. E., Stamps, L. D. & Wener, M. H. Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J. Rheumatol. 30, 1495\u20131504 (2003).","journal-title":"J. Rheumatol."},{"key":"653_CR75","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.4049\/jimmunol.142.9.3076","volume":"142","author":"E Raz","year":"1989","unstructured":"Raz, E., Brezis, M., Rosenmann, E. & Eilat, D. Anti-DNA antibodies bind directly to renal antigens and induce kidney dysfunction in the isolated perfused rat kidney. J. Immunol. 142, 3076\u20133082 (1989).","journal-title":"J. Immunol."},{"key":"653_CR76","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/ki.1995.341","volume":"48","author":"MR Ehrenstein","year":"1995","unstructured":"Ehrenstein, M. R. et al. Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int. 48, 705\u2013711 (1995).","journal-title":"Kidney Int."},{"key":"653_CR77","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1681\/ASN.2010050515","volume":"22","author":"M Espeli","year":"2011","unstructured":"Espeli, M. et al. Local renal autoantibody production in lupus nephritis. J. Am. Soc. Nephrol. 22, 296\u2013305 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"653_CR78","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1002\/art.38888","volume":"66","author":"AJ Kinloch","year":"2014","unstructured":"Kinloch, A. J. et al. Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis. Arthritis Rheumatol. 66, 3359\u20133370 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"653_CR79","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1093\/rheumatology\/keac083","volume":"61","author":"MJ Wahadat","year":"2022","unstructured":"Wahadat, M. J. et al. Gene signature fingerprints stratify SLE patients in groups with similar biological disease profiles: a multicentre longitudinal study. Rheumatology 61, 4344\u20134354 (2022).","journal-title":"Rheumatology"},{"key":"653_CR80","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1136\/annrheumdis-2013-203455","volume":"72","author":"Q Cheng","year":"2013","unstructured":"Cheng, Q. et al. Autoantibodies from long-lived \u2018memory\u2019 plasma cells of NZB\/W mice drive immune complex nephritis. Ann. Rheum. Dis. 72, 2011\u20132017 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR81","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar3909","volume":"14","author":"HE Mei","year":"2012","unstructured":"Mei, H. E., Schmidt, S. & D\u00f6rner, T. Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res. Ther. 14, S1 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"653_CR82","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41591-023-02479-1","volume":"29","author":"D Roccatello","year":"2023","unstructured":"Roccatello, D. et al. Daratumumab monotherapy for refractory lupus nephritis. Nat. Med. 29, 2041\u20132047 (2023).","journal-title":"Nat. Med."},{"key":"653_CR83","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41577-022-00816-y","volume":"23","author":"HJ Anders","year":"2023","unstructured":"Anders, H. J., Kitching, A. R., Leung, N. & Romagnani, P. Glomerulonephritis: immunopathogenesis and immunotherapy. Nat. Rev. Immunol. 23, 453\u2013471 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"653_CR84","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41584-024-01158-w","volume":"20","author":"J Lichtnekert","year":"2024","unstructured":"Lichtnekert, J. & Anders, H. J. Lupus nephritis-related chronic kidney disease. Nat. Rev. Rheumatol. 20, 699\u2013711 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"653_CR85","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/ndt\/gfad215","volume":"39","author":"Z Makhammajanov","year":"2024","unstructured":"Makhammajanov, Z. et al. Tubular toxicity of proteinuria and the progression of chronic kidney disease. Nephrol. Dial. Transpl. 39, 589\u2013599 (2024).","journal-title":"Nephrol. Dial. Transpl."},{"key":"653_CR86","doi-asserted-by":"publisher","unstructured":"Malvar, A. et al. Remission of lupus nephritis: the trajectory of histological response in successfully treated patients. Lupus Sci. Med. https:\/\/doi.org\/10.1136\/lupus-2023-000932 (2023). This study examines the histological progression of LN in patients achieving clinical remission, shedding light on the timeline and extent of kidney tissue recovery after treatment.","DOI":"10.1136\/lupus-2023-000932"},{"key":"653_CR87","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/ndt\/gfac304","volume":"38","author":"AA Perez-Arias","year":"2023","unstructured":"Perez-Arias, A. A. et al. The influence of repeated flares in response to therapy and prognosis in lupus nephritis. Nephrol. Dial. Transpl. 38, 884\u2013893 (2023).","journal-title":"Nephrol. Dial. Transpl."},{"key":"653_CR88","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41581-021-00510-7","volume":"18","author":"VA Luyckx","year":"2022","unstructured":"Luyckx, V. A. et al. Nephron overload as a therapeutic target to maximize kidney lifespan. Nat. Rev. Nephrol. 18, 171\u2013183 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"653_CR89","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrneph.2014.251","volume":"11","author":"VA Luyckx","year":"2015","unstructured":"Luyckx, V. A. & Brenner, B. M. Birth weight, malnutrition and kidney-associated outcomes-a global concern. Nat. Rev. Nephrol. 11, 135\u2013149 (2015).","journal-title":"Nat. Rev. Nephrol."},{"key":"653_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.88","volume":"3","author":"P Romagnani","year":"2017","unstructured":"Romagnani, P. et al. Chronic kidney disease. Nat. Rev. Dis. Primers\u00a03, 17088 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"653_CR91","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-022-00559-y","volume":"18","author":"M Cortinovis","year":"2022","unstructured":"Cortinovis, M., Perico, N., Ruggenenti, P., Remuzzi, A. & Remuzzi, G. Glomerular hyperfiltration. Nat. Rev. Nephrol. 18, 435\u2013451 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"653_CR92","first-page":"283","volume":"27","author":"J Font","year":"1987","unstructured":"Font, J. et al. Silent renal disease in systemic lupus erythematosus. Clin. Nephrol. 27, 283\u2013288 (1987).","journal-title":"Clin. Nephrol."},{"key":"653_CR93","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/IJWH.S28034","volume":"4","author":"CC Mok","year":"2012","unstructured":"Mok, C. C. Understanding lupus nephritis: diagnosis, management, and treatment options. Int. J. Womens Health 4, 213\u2013222 (2012).","journal-title":"Int. J. Womens Health"},{"key":"653_CR94","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"M Aringer","year":"2019","unstructured":"Aringer, M. et al. 2019 European League against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann. Rheum. Dis. 78, 1151\u20131159 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR95","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","volume":"65","author":"JJ Weening","year":"2004","unstructured":"Weening, J. J. et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 65, 521\u2013530 (2004).","journal-title":"Kidney Int."},{"key":"653_CR96","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/ki.2009.344","volume":"76","author":"DM Fine","year":"2009","unstructured":"Fine, D. M. et al. A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis. Kidney Int. 76, 1284\u20131288 (2009).","journal-title":"Kidney Int."},{"key":"653_CR97","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/sj.ki.5002421","volume":"72","author":"DJ Birmingham","year":"2007","unstructured":"Birmingham, D. J. et al. Spot urine protein\/creatinine ratios are unreliable estimates of 24 h proteinuria in most systemic lupus erythematosus nephritis flares. Kidney Int. 72, 865\u2013870 (2007).","journal-title":"Kidney Int."},{"key":"653_CR98","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1093\/ndt\/gfl159","volume":"21","author":"GR Bihl","year":"2006","unstructured":"Bihl, G. R., Petri, M. & Fine, D. M. Kidney biopsy in lupus nephritis: look before you leap. Nephrol. Dial. Transpl. 21, 1749\u20131752 (2006).","journal-title":"Nephrol. Dial. Transpl."},{"key":"653_CR99","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/0961203308100481","volume":"18","author":"C Gordon","year":"2009","unstructured":"Gordon, C. et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 18, 257\u2013263 (2009).","journal-title":"Lupus"},{"key":"653_CR100","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","volume":"71","author":"GK Bertsias","year":"2012","unstructured":"Bertsias, G. K. et al. Joint European League against Rheumatism and European Renal Association\u2013European Dialysis and Transplant Association (EULAR\/ERA\u2013EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann. Rheum. Dis. 71, 1771\u20131782 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR101","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","volume":"79","author":"A Fanouriakis","year":"2020","unstructured":"Fanouriakis, A. et al. 2019 update of the joint European League against Rheumatism and European Renal Association\u2013European Dialysis and Transplant Association (EULAR\/ERA\u2013EDTA) recommendations for the management of lupus nephritis. Ann. Rheum. Dis. 79, 713\u2013723 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR102","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.ekir.2019.04.013","volume":"4","author":"JL Rosenstock","year":"2019","unstructured":"Rosenstock, J. L. & Markowitz, G. S. Fibrillary glomerulonephritis: an update. Kidney Int. Rep. 4, 917\u2013922 (2019).","journal-title":"Kidney Int. Rep."},{"key":"653_CR103","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s10067-022-06394-7","volume":"42","author":"ES Kang","year":"2023","unstructured":"Kang, E. S. et al. Risk of bleeding-related complications after kidney biopsy in patients with systemic lupus erythematosus. Clin. Rheumatol. 42, 751\u2013759 (2023).","journal-title":"Clin. Rheumatol."},{"key":"653_CR104","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2014-000061","volume":"2","author":"I Parodis","year":"2015","unstructured":"Parodis, I. et al. Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy. Lupus Sci. Med. 2, e000061 (2015).","journal-title":"Lupus Sci. Med."},{"key":"653_CR105","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/acr.22200","volume":"66","author":"N Jordan","year":"2014","unstructured":"Jordan, N. et al. Association of thrombotic microangiopathy and intimal hyperplasia with bleeding post-renal biopsy in antiphospholipid antibody-positive patients. Arthritis Care Res. 66, 725\u2013731 (2014).","journal-title":"Arthritis Care Res."},{"key":"653_CR106","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00005-022-00646-9","volume":"70","author":"I Parodis","year":"2022","unstructured":"Parodis, I., Tamirou, F. & Houssiau, F. A. Treat-to-target in lupus nephritis. What is the role of the repeat kidney biopsy? Arch. Immunol. Ther. Exp. 70, 8 (2022).","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"653_CR107","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2014-000018","volume":"1","author":"A Zickert","year":"2014","unstructured":"Zickert, A., Sundelin, B., Svenungsson, E. & Gunnarsson, I. Role of early repeated renal biopsies in lupus nephritis. Lupus Sci. Med. 1, e000018 (2014).","journal-title":"Lupus Sci. Med."},{"key":"653_CR108","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/ndt\/gfv296","volume":"32","author":"A Malvar","year":"2017","unstructured":"Malvar, A. et al. Histologic versus clinical remission in proliferative lupus nephritis. Nephrol. Dial. Transpl. 32, 1338\u20131344 (2017).","journal-title":"Nephrol. Dial. Transpl."},{"key":"653_CR109","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.kint.2018.05.021","volume":"94","author":"M De Rosa","year":"2018","unstructured":"De Rosa, M. et al. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int. 94, 788\u2013794 (2018).","journal-title":"Kidney Int."},{"key":"653_CR110","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1093\/rheumatology\/keaa129","volume":"59","author":"I Parodis","year":"2020","unstructured":"Parodis, I. et al. Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis. Rheumatology 59, 3424\u20133434 (2020).","journal-title":"Rheumatology"},{"key":"653_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103422","volume":"23","author":"I Parodis","year":"2024","unstructured":"Parodis, I., Moroni, G., Calatroni, M., Bellis, E. & Gatto, M. Is per-protocol kidney biopsy required in lupus nephritis? Autoimmun. Rev. 23, 103422 (2024).","journal-title":"Autoimmun. Rev."},{"key":"653_CR112","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.kint.2019.07.018","volume":"97","author":"A Malvar","year":"2020","unstructured":"Malvar, A. et al. Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis. Kidney Int. 97, 156\u2013162 (2020).","journal-title":"Kidney Int."},{"key":"653_CR113","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","volume":"93","author":"IM Bajema","year":"2018","unstructured":"Bajema, I. M. et al. Revision of the International society of nephrology\/Renal pathology society classification for lupus nephritis: clarification of definitions, and modified national institutes of health activity and chronicity indices. Kidney Int. 93, 789\u2013796 (2018).","journal-title":"Kidney Int."},{"key":"653_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109713","volume":"254","author":"ASC Louis Sam Titus","year":"2023","unstructured":"Louis Sam Titus, A. S. C. et al. Molecular architecture of proliferative lupus nephritis as elucidated using 50-plex imaging mass cytometry proteomics. Clin. Immunol. 254, 109713 (2023).","journal-title":"Clin. Immunol."},{"key":"653_CR115","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1159\/000179336","volume":"1","author":"CL Pirani","year":"1964","unstructured":"Pirani, C. L., Pollak, V. E. & Schwartz, F. D. THE reproducibility of semiquantitative analyses of renal histology. Nephron 1, 230\u2013237 (1964).","journal-title":"Nephron"},{"key":"653_CR116","first-page":"79","volume":"6","author":"L Morel-Maroger","year":"1976","unstructured":"Morel-Maroger, L. et al. The course of lupus nephritis: contribution of serial renal biopsies. Adv. Nephrol. Necker Hosp. 6, 79\u2013118 (1976).","journal-title":"Adv. Nephrol. Necker Hosp."},{"key":"653_CR117","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/0002-9343(83)90338-8","volume":"75","author":"HA Austin","year":"1983","unstructured":"Austin, H. A. et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am. J. Med. 75, 382\u2013391 (1983).","journal-title":"Am. J. Med."},{"key":"653_CR118","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1191\/0961203305lu2238oa","volume":"14","author":"G Contreras","year":"2005","unstructured":"Contreras, G. et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus 14, 890\u2013895 (2005).","journal-title":"Lupus"},{"key":"653_CR119","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/S0272-6386(12)80263-0","volume":"21","author":"MM Schwartz","year":"1993","unstructured":"Schwartz, M. M. et al. Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis. Lupus nephritis collaborative study group. Am. J. Kidney Dis. 21, 374\u2013377 (1993).","journal-title":"Am. J. Kidney Dis."},{"key":"653_CR120","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.kint.2023.02.006","volume":"103","author":"IM Bajema","year":"2023","unstructured":"Bajema, I. M. et al. Update on scoring and providing evidence basis for assessing pathology in lupus nephritis. Kidney Int. 103, 813\u2013816 (2023).","journal-title":"Kidney Int."},{"key":"653_CR121","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1681\/ASN.V13142","volume":"13","author":"E Daugas","year":"2002","unstructured":"Daugas, E. et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J. Am. Soc. Nephrol. 13, 42\u201352 (2002).","journal-title":"J. Am. Soc. Nephrol."},{"key":"653_CR122","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.20433","volume":"50","author":"MG Tektonidou","year":"2004","unstructured":"Tektonidou, M. G., Sotsiou, F., Nakopoulou, L., Vlachoyiannopoulos, P. G. & Moutsopoulos, H. M. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum. 50, 2569\u20132579 (2004).","journal-title":"Arthritis Rheum."},{"key":"653_CR123","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1136\/ard-2023-224609","volume":"82","author":"M Barbhaiya","year":"2023","unstructured":"Barbhaiya, M. et al. 2023 ACR\/EULAR antiphospholipid syndrome classification criteria. Ann. Rheum. Dis. 82, 1258\u20131270 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR124","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3899\/jrheum.2022-1200","volume":"51","author":"M Barbhaiya","year":"2024","unstructured":"Barbhaiya, M. et al. Efforts to better characterize \u201cAntiphospholipid Antibody Nephropathy\u201d for the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria: renal pathology subcommittee report. J. Rheumatol. 51, 150\u2013159 (2024).","journal-title":"J. Rheumatol."},{"key":"653_CR125","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13075-015-0614-5","volume":"17","author":"J Gerhardsson","year":"2015","unstructured":"Gerhardsson, J. et al. Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up. Arthritis Res. Ther. 17, 109 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"653_CR126","doi-asserted-by":"publisher","DOI":"10.1186\/ar4142","volume":"15","author":"D Song","year":"2013","unstructured":"Song, D. et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res. Ther. 15, R12 (2013).","journal-title":"Arthritis Res. Ther."},{"key":"653_CR127","doi-asserted-by":"publisher","DOI":"10.1186\/ar2736","volume":"11","author":"H Zheng","year":"2009","unstructured":"Zheng, H. et al. Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: a prospective study of 124 cases. Arthritis Res. Ther. 11, R93 (2009).","journal-title":"Arthritis Res. Ther."},{"key":"653_CR128","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3389\/fimmu.2018.01181","volume":"9","author":"MG Tektonidou","year":"2018","unstructured":"Tektonidou, M. G. Antiphospholipid syndrome nephropathy: from pathogenesis to treatment. Front. Immunol. 9, 1181 (2018).","journal-title":"Front. Immunol."},{"key":"653_CR129","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158076","volume":"11","author":"I Parodis","year":"2016","unstructured":"Parodis, I. et al. Antiphospholipid antibodies in lupus nephritis. PLoS ONE 11, e0158076 (2016).","journal-title":"PLoS ONE"},{"key":"653_CR130","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.kint.2024.09.007","volume":"106","author":"S Vodehnal","year":"2024","unstructured":"Vodehnal, S. & Mohan, C. Urinary biomarkers for active lupus nephritis that have survived independent validation across cohorts. Kidney Int. 106, 1135\u20131145 (2024).","journal-title":"Kidney Int."},{"key":"653_CR131","doi-asserted-by":"publisher","unstructured":"Palazzo, L., Lindblom, J., Mohan, C. & Parodis, I. Current insights on biomarkers in lupus nephritis: a systematic review of the literature. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm11195759 (2022). This systematic review evaluates emerging and established biomarkers in LN, focusing on their potential to improve diagnosis, disease monitoring and treatment response assessment.","DOI":"10.3390\/jcm11195759"},{"key":"653_CR132","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/MAJ.0b013e3181907b3d","volume":"337","author":"S Singh","year":"2009","unstructured":"Singh, S. & Saxena, R. Lupus nephritis. Am. J. Med. Sci. 337, 451\u2013460 (2009).","journal-title":"Am. J. Med. Sci."},{"key":"653_CR133","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/acr.23887","volume":"72","author":"E Maningding","year":"2020","unstructured":"Maningding, E., Dall\u2019Era, M., Trupin, L., Murphy, L. B. & Yazdany, J. Racial and ethnic differences in the prevalence and time to onset of manifestations of systemic lupus erythematosus: the California lupus surveillance project. Arthritis Care Res. 72, 622\u2013629 (2020).","journal-title":"Arthritis Care Res."},{"key":"653_CR134","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2015-000123","volume":"2","author":"F Tamirou","year":"2015","unstructured":"Tamirou, F. et al. A proteinuria cut-off level of 0.7 g\/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN nephritis trial. Lupus Sci. Med. 2, e000123 (2015).","journal-title":"Lupus Sci. Med."},{"key":"653_CR135","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1002\/art.39026","volume":"67","author":"M Dall\u2019Era","year":"2015","unstructured":"Dall\u2019Era, M. et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro\u2013Lupus Nephritis cohort. Arthritis Rheumatol. 67, 1305\u20131313 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"653_CR136","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2017-000213","volume":"4","author":"MR Ugolini-Lopes","year":"2017","unstructured":"Ugolini-Lopes, M. R. et al. Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis? Lupus Sci. Med. 4, e000213 (2017).","journal-title":"Lupus Sci. Med."},{"key":"653_CR137","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000389","volume":"7","author":"I Parodis","year":"2020","unstructured":"Parodis, I., Tamirou, F. & Houssiau, F. A. Prediction of prognosis and renal outcome in lupus nephritis. Lupus Sci. Med. 7, e000389 (2020).","journal-title":"Lupus Sci. Med."},{"key":"653_CR138","doi-asserted-by":"publisher","unstructured":"Parodis, I. et al. B cell kinetics upon therapy commencement for active extrarenal systemic lupus erythematosus in relation to development of renal flares: results from three phase III clinical trials of belimumab. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms232213941 (2022).","DOI":"10.3390\/ijms232213941"},{"key":"653_CR139","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae023","author":"S J\u00e4gerback","year":"2024","unstructured":"J\u00e4gerback, S., Gomez, A. & Parodis, I. Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab. Rheumatology https:\/\/doi.org\/10.1093\/rheumatology\/keae023 (2024).","journal-title":"Rheumatology"},{"key":"653_CR140","doi-asserted-by":"publisher","first-page":"106904","DOI":"10.1155\/2015\/106904","volume":"2015","author":"G Moroni","year":"2015","unstructured":"Moroni, G. et al. The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy. J. Immunol. Res. 2015, 106904 (2015).","journal-title":"J. Immunol. Res."},{"key":"653_CR141","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1136\/ard.2004.024943","volume":"64","author":"N Marto","year":"2005","unstructured":"Marto, N., Bertolaccini, M. L., Calabuig, E., Hughes, G. R. & Khamashta, M. A. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann. Rheum. Dis. 64, 444\u2013448 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR142","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1136\/ard.2008.094508","volume":"68","author":"G Moroni","year":"2009","unstructured":"Moroni, G. et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann. Rheum. Dis. 68, 234\u2013237 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR143","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1007\/s00296-011-1962-3","volume":"32","author":"H Julkunen","year":"2012","unstructured":"Julkunen, H., Ekblom-Kullberg, S. & Miettinen, A. Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4. Rheumatol. Int. 32, 2445\u20132451 (2012).","journal-title":"Rheumatol. Int."},{"key":"653_CR144","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1093\/ndt\/gfs179","volume":"27","author":"XW Yang","year":"2012","unstructured":"Yang, X. W., Tan, Y., Yu, F. & Zhao, M. H. Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis. Nephrol. Dial. Transpl. 27, 3552\u20133559 (2012).","journal-title":"Nephrol. Dial. Transpl."},{"key":"653_CR145","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/0961203314547791","volume":"24","author":"AM Orbai","year":"2015","unstructured":"Orbai, A. M. et al. Anti-C1q antibodies in systemic lupus erythematosus. Lupus 24, 42\u201349 (2015).","journal-title":"Lupus"},{"key":"653_CR146","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/ndt\/gfn453","volume":"24","author":"QY Fang","year":"2009","unstructured":"Fang, Q. Y. et al. Anti-C1q antibodies and IgG subclass distribution in sera from Chinese patients with lupus nephritis. Nephrol. Dial. Transpl. 24, 172\u2013178 (2009).","journal-title":"Nephrol. Dial. Transpl."},{"key":"653_CR147","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1016\/j.molimm.2009.04.030","volume":"46","author":"Y Tan","year":"2009","unstructured":"Tan, Y. et al. Detection of anti-C1q antibodies and anti-C1q globular head domain antibodies in sera from Chinese patients with lupus nephritis. Mol. Immunol. 46, 2178\u20132182 (2009).","journal-title":"Mol. Immunol."},{"key":"653_CR148","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.kint.2016.08.010","volume":"90","author":"Y Pang","year":"2016","unstructured":"Pang, Y. et al. Serum A08 C1q antibodies are associated with disease activity and prognosis in Chinese patients with lupus nephritis. Kidney Int. 90, 1357\u20131367 (2016).","journal-title":"Kidney Int."},{"key":"653_CR149","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1002\/art.30401","volume":"63","author":"Y Katsumata","year":"2011","unstructured":"Katsumata, Y. et al. Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: a controlled study of 126 consecutive patients. Arthritis Rheum. 63, 2436\u20132444 (2011).","journal-title":"Arthritis Rheum."},{"key":"653_CR150","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.humimm.2008.09.006","volume":"69","author":"Y Tan","year":"2008","unstructured":"Tan, Y. et al. Autoantibodies against monomeric C-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions. Hum. Immunol. 69, 840\u2013844 (2008).","journal-title":"Hum. Immunol."},{"key":"653_CR151","doi-asserted-by":"publisher","first-page":"R188","DOI":"10.1186\/ar2880","volume":"11","author":"C Sj\u00f6wall","year":"2009","unstructured":"Sj\u00f6wall, C., Zickert, A., Skogh, T., Wetter\u00f6, J. & Gunnarsson, I. Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis. Arthritis Res. Ther. 11, R188 (2009).","journal-title":"Arthritis Res. Ther."},{"key":"653_CR152","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1681\/ASN.2016070735","volume":"28","author":"QY Li","year":"2017","unstructured":"Li, Q. Y. et al. Autoantibodies against C-reactive protein influence complement activation and clinical course in lupus nephritis. J. Am. Soc. Nephrol. 28, 3044\u20133054 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"653_CR153","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/rheumatology\/kes252","volume":"52","author":"A Vikerfors","year":"2013","unstructured":"Vikerfors, A. et al. Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. Rheumatology 52, 501\u2013509 (2013).","journal-title":"Rheumatology"},{"key":"653_CR154","doi-asserted-by":"publisher","unstructured":"Panagiotopoulos, A. et al. Disease modification achievement in patients with lupus nephritis in a real-life setting: mission impossible? RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2023-003158 (2023).","DOI":"10.1136\/rmdopen-2023-003158"},{"key":"653_CR155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00041552-200501000-00002","volume":"14","author":"B Mittal","year":"2005","unstructured":"Mittal, B., Rennke, H. & Singh, A. K. The role of kidney biopsy in the management of lupus nephritis. Curr. Opin. Nephrol. Hypertens. 14, 1\u20138 (2005).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"653_CR156","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1136\/ard.62.5.435","volume":"62","author":"C Fiehn","year":"2003","unstructured":"Fiehn, C. et al. Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann. Rheum. Dis. 62, 435\u2013439 (2003).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR157","first-page":"1464","volume":"33","author":"C Fiehn","year":"2006","unstructured":"Fiehn, C. Early diagnosis and treatment in lupus nephritis: how we can influence the risk for terminal renal failure. J. Rheumatol. 33, 1464\u20131466 (2006).","journal-title":"J. Rheumatol."},{"key":"653_CR158","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081483","volume":"8","author":"F Yuan","year":"2013","unstructured":"Yuan, F. et al. A dexamethasone prodrug reduces the renal macrophage response and provides enhanced resolution of established murine lupus nephritis. PLoS ONE\u00a08, e81483 (2013).","journal-title":"PLoS ONE"},{"key":"653_CR159","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.3899\/jrheum.170158","volume":"44","author":"JW Kim","year":"2017","unstructured":"Kim, J. W. et al. Risk of retinal toxicity in longterm users of hydroxychloroquine. J. Rheumatol. 44, 1674\u20131679 (2017).","journal-title":"J. Rheumatol."},{"key":"653_CR160","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","volume":"132","author":"RB Melles","year":"2014","unstructured":"Melles, R. B. & Marmor, M. F. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 132, 1453\u20131460 (2014).","journal-title":"JAMA Ophthalmol."},{"key":"653_CR161","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ophtha.2010.11.017","volume":"118","author":"MF Marmor","year":"2011","unstructured":"Marmor, M. F., Kellner, U., Lai, T. Y., Lyons, J. S. & Mieler, W. F. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 118, 415\u2013422 (2011).","journal-title":"Ophthalmology"},{"key":"653_CR162","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/nrneph.2011.150","volume":"7","author":"SJ Lee","year":"2011","unstructured":"Lee, S. J., Silverman, E. & Bargman, J. M. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat. Rev. Nephrol. 7, 718\u2013729 (2011).","journal-title":"Nat. Rev. Nephrol."},{"key":"653_CR163","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/rheumatology\/kead253","volume":"63","author":"A Gomez","year":"2024","unstructured":"Gomez, A., J\u00e4gerback, S., Sj\u00f6wall, C. & Parodis, I. Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials. Rheumatology 63, 338\u2013348 (2024).","journal-title":"Rheumatology"},{"key":"653_CR164","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3109\/01913123.2012.751950","volume":"37","author":"SR Khubchandani","year":"2013","unstructured":"Khubchandani, S. R. & Bichle, L. S. Hydroxychloroquine-induced phospholipidosis in a case of SLE: the wolf in zebra clothing. Ultrastruct. Pathol. 37, 146\u2013150 (2013).","journal-title":"Ultrastruct. Pathol."},{"key":"653_CR165","doi-asserted-by":"publisher","unstructured":"Longhitano, E. et al. Proteinuria and progression of renal damage: the main pathogenetic mechanisms and pharmacological approach. Medicina https:\/\/doi.org\/10.3390\/medicina60111821 (2024).","DOI":"10.3390\/medicina60111821"},{"key":"653_CR166","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1056\/NEJM197811232992102","volume":"299","author":"JV Donadio Jr.","year":"1978","unstructured":"Donadio, J. V. Jr., Holley, K. E., Ferguson, R. H. & Ilstrup, D. M. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N. Engl. J. Med. 299, 1151\u20131155 (1978).","journal-title":"N. Engl. J. Med."},{"key":"653_CR167","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJM198603063141004","volume":"314","author":"HA Austin 3rd","year":"1986","unstructured":"Austin, H. A. 3rd et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N. Engl. J. Med. 314, 614\u2013619 (1986).","journal-title":"N. Engl. J. Med."},{"key":"653_CR168","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1002\/art.10461","volume":"46","author":"FA Houssiau","year":"2002","unstructured":"Houssiau, F. A. et al. Immunosuppressive therapy in lupus nephritis: the Euro\u2013Lupus Nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 46, 2121\u20132131 (2002).","journal-title":"Arthritis Rheum."},{"key":"653_CR169","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","volume":"343","author":"TM Chan","year":"2000","unstructured":"Chan, T. M. et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong\u2013Guangzhou nephrology study group. N. Engl. J. Med. 343, 1156\u20131162 (2000).","journal-title":"N. Engl. J. Med."},{"key":"653_CR170","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa043731","volume":"353","author":"EM Ginzler","year":"2005","unstructured":"Ginzler, E. M. et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353, 2219\u20132228 (2005).","journal-title":"N. Engl. J. Med."},{"key":"653_CR171","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel, G. B. et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20, 1103\u20131112 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"653_CR172","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/annrheumdis-2021-221270","volume":"81","author":"I Parodis","year":"2022","unstructured":"Parodis, I. & Houssiau, F. A. From sequential to combination and personalised therapy in lupus nephritis: moving towards a paradigm shift? Ann. Rheum. Dis. 81, 15\u201319 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR173","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","volume":"95","author":"BH Rovin","year":"2019","unstructured":"Rovin, B. H. et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 95, 219\u2013231 (2019).","journal-title":"Kidney Int."},{"key":"653_CR174","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin, B. H. et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397, 2070\u20132080 (2021).","journal-title":"Lancet"},{"key":"653_CR175","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie, R. et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N. Engl. J. Med. 383, 1117\u20131128 (2020).","journal-title":"N. Engl. J. Med."},{"key":"653_CR176","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410965","author":"RA Furie","year":"2025","unstructured":"Furie, R. A. et al. Efficacy and safety of obinutuzumab in active lupus nephritis. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2410965 (2025).","journal-title":"N. Engl. J. Med."},{"key":"653_CR177","doi-asserted-by":"publisher","first-page":"103418","DOI":"10.1016\/j.autrev.2023.103418","volume":"23","author":"I Parodis","year":"2024","unstructured":"Parodis, I., Depascale, R., Doria, A. & Anders, H. J. When should targeted therapies be used in the treatment of lupus nephritis: early in the disease course or in refractory patients? Autoimmun. Rev. 23, 103418 (2024).","journal-title":"Autoimmun. Rev."},{"key":"653_CR178","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/ndt\/gfad167","volume":"38","author":"HJ Anders","year":"2023","unstructured":"Anders, H. J. et al. Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial. Nephrol. Dial. Transpl. 38, 2733\u20132742 (2023).","journal-title":"Nephrol. Dial. Transpl."},{"key":"653_CR179","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1053\/j.ajkd.2022.06.013","volume":"81","author":"X Yu","year":"2023","unstructured":"Yu, X. et al. Efficacy and safety of belimumab in patients with lupus nephritis: subgroup analyses of a phase 3 randomized trial in the East Asian population. Am. J. Kidney Dis. 81, 294\u2013306.e291 (2023).","journal-title":"Am. J. Kidney Dis."},{"key":"653_CR180","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.kint.2021.12.003","volume":"101","author":"S Gleeson","year":"2022","unstructured":"Gleeson, S. & Lightstone, L. BLISS-LN trial revisited: function matters. Kidney Int. 101, 224\u2013226 (2022).","journal-title":"Kidney Int."},{"key":"653_CR181","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.2215\/CJN.02520322","volume":"17","author":"R Furie","year":"2022","unstructured":"Furie, R. et al. Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study. Clin. J. Am. Soc. Nephrol. 17, 1620\u20131630 (2022).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"653_CR182","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","volume":"101","author":"BH Rovin","year":"2022","unstructured":"Rovin, B. H. et al. A secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 101, 403\u2013413 (2022).","journal-title":"Kidney Int."},{"key":"653_CR183","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/art.42657","volume":"76","author":"A Saxena","year":"2024","unstructured":"Saxena, A. et al. Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial. Arthritis Rheumatol. 76, 59\u201367 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"653_CR184","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/acr.25007","volume":"75","author":"C Arriens","year":"2023","unstructured":"Arriens, C. et al. Update on the efficacy and safety profile of voclosporin: an integrated analysis of clinical trials in lupus nephritis. Arthritis Care Res. 75, 1399\u20131408 (2023).","journal-title":"Arthritis Care Res."},{"key":"653_CR185","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae381","author":"A Panagiotopoulos","year":"2024","unstructured":"Panagiotopoulos, A. et al. Immunosuppressives discontinuation after renal response in lupus nephritis: predictors of flares, time to withdrawal and long-term outcomes. Rheumatology https:\/\/doi.org\/10.1093\/rheumatology\/keae381 (2024). This study investigates the outcomes of immunosuppressive withdrawal in patients with LN after achieving renal response, identifying predictors of disease flares and long-term prognosis.","journal-title":"Rheumatology"},{"key":"653_CR186","doi-asserted-by":"publisher","first-page":"103810","DOI":"10.1016\/j.autrev.2025.103810","volume":"24","author":"I Parodis","year":"2025","unstructured":"Parodis, I. et al. Lupus nephritis trials network (LNTN) repeat kidney biopsy-based definitions of treatment response: a systematic literature review-based proposal. Autoimmun. Rev. 24, 103810 (2025).","journal-title":"Autoimmun. Rev."},{"key":"653_CR187","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1056\/NEJMoa031855","volume":"350","author":"G Contreras","year":"2004","unstructured":"Contreras, G. et al. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 350, 971\u2013980 (2004).","journal-title":"N. Engl. J. Med."},{"key":"653_CR188","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/ard.2008.102533","volume":"69","author":"FA Houssiau","year":"2010","unstructured":"Houssiau, F. A. et al. The 10-year follow-up data of the Euro\u2013Lupus Nephritis trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann. Rheum. Dis. 69, 61\u201364 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR189","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","volume":"365","author":"MA Dooley","year":"2011","unstructured":"Dooley, M. A. et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N. Engl. J. Med. 365, 1886\u20131895 (2011).","journal-title":"N. Engl. J. Med."},{"key":"653_CR190","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/annrheumdis-2014-206897","volume":"75","author":"F Tamirou","year":"2016","unstructured":"Tamirou, F. et al. Long-term follow-up of the MAINTAIN Nephritis trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann. Rheum. Dis. 75, 526\u2013531 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR191","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/sj.ki.5002215","volume":"71","author":"M Praga","year":"2007","unstructured":"Praga, M., Barrio, V., Ju\u00e1rez, G. F. & Lu\u00f1o, J. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 71, 924\u2013930 (2007).","journal-title":"Kidney Int."},{"key":"653_CR192","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S0140-6736(12)61566-9","volume":"381","author":"A Howman","year":"2013","unstructured":"Howman, A. et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 381, 744\u2013751 (2013).","journal-title":"Lancet"},{"key":"653_CR193","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza, F. C. et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N. Engl. J. Med. 381, 36\u201346 (2019).","journal-title":"N. Engl. J. Med."},{"key":"653_CR194","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/acr.21664","volume":"64","author":"BH Hahn","year":"2012","unstructured":"Hahn, B. H. et al. American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 64, 797\u2013808 (2012).","journal-title":"Arthritis Care Res."},{"key":"653_CR195","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/art.42386","volume":"75","author":"AR Bass","year":"2023","unstructured":"Bass, A. R. et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 75, 333\u2013348 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"653_CR196","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","volume":"81","author":"GC Drosos","year":"2022","unstructured":"Drosos, G. C. et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann. Rheum. Dis. 81, 768\u2013779 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR197","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S2665-9913(24)00090-0","volume":"6","author":"E Bolla","year":"2024","unstructured":"Bolla, E. et al. Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries. Lancet Rheumatol. 6, e447\u2013e459 (2024).","journal-title":"Lancet Rheumatol."},{"key":"653_CR198","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1093\/rheumatology\/kew231","volume":"55","author":"M Iudici","year":"2016","unstructured":"Iudici, M. et al. Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study. Rheumatology 55, 1623\u20131630 (2016).","journal-title":"Rheumatology"},{"key":"653_CR199","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-019-0667-1","volume":"15","author":"C Gu","year":"2019","unstructured":"Gu, C. et al. A meta-analysis of secondary osteoporosis in systemic lupus erythematosus: prevalence and risk factors. Arch. Osteoporos. 15, 1 (2019).","journal-title":"Arch. Osteoporos."},{"key":"653_CR200","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/art.40818","volume":"71","author":"SK Tedeschi","year":"2019","unstructured":"Tedeschi, S. K., Kim, S. C., Guan, H., Grossman, J. M. & Costenbader, K. H. Comparative fracture risks among United States Medicaid enrollees with and those without systemic lupus erythematosus. Arthritis Rheumatol. 71, 1141\u20131146 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"653_CR201","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1002\/art.42646","volume":"75","author":"MB Humphrey","year":"2023","unstructured":"Humphrey, M. B. et al. 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 75, 2088\u20132102 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"653_CR202","volume":"16","author":"F Tariq","year":"2024","unstructured":"Tariq, F. et al. The management of osteoporosis in chronic kidney disease: a review of diagnostic and therapeutic approaches. Cureus 16, e73882 (2024).","journal-title":"Cureus"},{"key":"653_CR203","doi-asserted-by":"publisher","first-page":"953","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00004","volume":"142","author":"JP Buyon","year":"2005","unstructured":"Buyon, J. P. et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann. Intern. Med. 142, 953\u2013962 (2005).","journal-title":"Ann. Intern. Med."},{"key":"653_CR204","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jamaoncol.2015.3251","volume":"2","author":"RR Munhoz","year":"2016","unstructured":"Munhoz, R. R. et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2, 65\u201373 (2016).","journal-title":"JAMA Oncol."},{"key":"653_CR205","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1053\/j.ajkd.2004.01.008","volume":"43","author":"S Pendse","year":"2004","unstructured":"Pendse, S., Ginsburg, E. & Singh, A. K. Strategies for preservation of ovarian and testicular function after immunosuppression. Am. J. Kidney Dis. 43, 772\u2013781 (2004).","journal-title":"Am. J. Kidney Dis."},{"key":"653_CR206","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta12060","volume":"12","author":"CA Meads","year":"2008","unstructured":"Meads, C. A. et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol. Assess. 12, 1\u2013270 (2008).","journal-title":"Health Technol. Assess."},{"key":"653_CR207","doi-asserted-by":"publisher","unstructured":"ACOG Committee opinion no. 743 summary: low-dose aspirin use during pregnancy. Obstet. Gynecol. https:\/\/doi.org\/10.1097\/aog.0000000000002709 (2018).","DOI":"10.1097\/aog.0000000000002709"},{"key":"653_CR208","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa051135","volume":"353","author":"M Petri","year":"2005","unstructured":"Petri, M. et al. Combined oral contraceptives in women with systemic lupus erythematosus. N. Engl. J. Med. 353, 2550\u20132558 (2005).","journal-title":"N. Engl. J. Med."},{"key":"653_CR209","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","volume":"76","author":"L Andreoli","year":"2017","unstructured":"Andreoli, L. et al. EULAR recommendations for women\u2019s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome. Ann. Rheum. Dis. 76, 476\u2013485 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR210","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.kint.2022.10.029","volume":"103","author":"F Fakhouri","year":"2023","unstructured":"Fakhouri, F. et al. Glomerular diseases in pregnancy: pragmatic recommendations for clinical management. Kidney Int. 103, 264\u2013281 (2023).","journal-title":"Kidney Int."},{"key":"653_CR211","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1055\/s-0044-1790225","volume":"42","author":"L He","year":"2024","unstructured":"He, L. & Sims, C. Impact of antiphospholipid syndrome on reproductive outcomes: current insights and management approaches. Semin. Reprod. Med. 42, 197\u2013208 (2024).","journal-title":"Semin. Reprod. Med."},{"key":"653_CR212","doi-asserted-by":"publisher","unstructured":"Emamikia, S., Gentline, C., Enman, Y. & Parodis, I. How can we enhance adherence to medications in patients with systemic lupus erythematosus? Results from a qualitative study. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm11071857 (2022).","DOI":"10.3390\/jcm11071857"},{"key":"653_CR213","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/ard-2023-224416","volume":"83","author":"I Parodis","year":"2024","unstructured":"Parodis, I. et al. EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. Ann. Rheum. Dis. 83, 720\u2013729 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR214","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1177\/09612033241242692","volume":"33","author":"S Emamikia","year":"2024","unstructured":"Emamikia, S. et al. Factors associated with non-adherence to medications in systemic lupus erythematosus: results from a Swedish survey. Lupus 33, 615\u2013628 (2024).","journal-title":"Lupus"},{"key":"653_CR215","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1177\/0961203319877237","volume":"28","author":"M Oliveira-Santos","year":"2019","unstructured":"Oliveira-Santos, M., Verani, J. F. S., Camacho, L. A. B., de Andrade, C. A. F. & Klumb, E. M. Effectiveness of pharmaceutical care for drug treatment adherence in women with lupus nephritis in Rio de Janeiro, Brazil: a randomized controlled trial. Lupus 28, 1368\u20131377 (2019).","journal-title":"Lupus"},{"key":"653_CR216","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000602","volume":"9","author":"SJ Balevic","year":"2022","unstructured":"Balevic, S. J. et al. Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes. Lupus Sci. Med. 9, e000602 (2022).","journal-title":"Lupus Sci. Med."},{"key":"653_CR217","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/acr.23792","volume":"71","author":"CH Feldman","year":"2019","unstructured":"Feldman, C. H. et al. Azathioprine and mycophenolate mofetil adherence patterns and predictors among medicaid beneficiaries with systemic lupus erythematosus. Arthritis Care Res. 71, 1419\u20131424 (2019).","journal-title":"Arthritis Care Res."},{"key":"653_CR218","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.semarthrit.2018.01.002","volume":"48","author":"CH Feldman","year":"2018","unstructured":"Feldman, C. H. et al. Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus. Semin. Arthritis Rheum. 48, 205\u2013213 (2018).","journal-title":"Semin. Arthritis Rheum."},{"key":"653_CR219","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.kint.2020.10.037","volume":"99","author":"N Costedoat-Chalumeau","year":"2021","unstructured":"Costedoat-Chalumeau, N. & Houssiau, F. A. Improving medication adherence in patients with lupus nephritis. Kidney Int. 99, 285\u2013287 (2021).","journal-title":"Kidney Int."},{"key":"653_CR220","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2174\/1573397115666190626111847","volume":"16","author":"AY Ali","year":"2020","unstructured":"Ali, A. Y., Abdelaziz, T. S. & Behiry, M. E. The prevalence and causes of non-adherence to immunosuppressive medications in patients with lupus nephritis flares. Curr. Rheumatol. Rev. 16, 245\u2013248 (2020).","journal-title":"Curr. Rheumatol. Rev."},{"key":"653_CR221","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1177\/09612033221100910","volume":"31","author":"S Kharawala","year":"2022","unstructured":"Kharawala, S. et al. Health-related quality of life, fatigue and health utilities in lupus nephritis: a systematic literature review. Lupus 31, 1029\u20131044 (2022).","journal-title":"Lupus"},{"key":"653_CR222","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3899\/jrheum.080822","volume":"36","author":"S Appenzeller","year":"2009","unstructured":"Appenzeller, S. et al. The relationship between renal activity and quality of life in systemic lupus erythematosus. J. Rheumatol. 36, 947\u2013952 (2009).","journal-title":"J. Rheumatol."},{"key":"653_CR223","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12865-017-0200-5","volume":"18","author":"B Chaigne","year":"2017","unstructured":"Chaigne, B. et al. Impact of disease activity on health-related quality of life in systemic lupus erythematosus \u2014 a cross-sectional analysis of the Swiss systemic lupus erythematosus cohort study (SSCS). BMC Immunol. 18, 17 (2017).","journal-title":"BMC Immunol."},{"key":"653_CR224","doi-asserted-by":"publisher","DOI":"10.1186\/s40359-023-01300-5","volume":"11","author":"S Hashemi","year":"2023","unstructured":"Hashemi, S. et al. Health-related quality of life and its related factors in patients with systemic lupus erythematosus in southwest Iran: a cross-sectional study. BMC Psychol. 11, 259 (2023).","journal-title":"BMC Psychol."},{"key":"653_CR225","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1093\/rheumatology\/keh392","volume":"43","author":"A Doria","year":"2004","unstructured":"Doria, A. et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology 43, 1580\u20131586 (2004).","journal-title":"Rheumatology"},{"key":"653_CR226","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3899\/jrheum.090876","volume":"37","author":"TY Zhu","year":"2010","unstructured":"Zhu, T. Y., Tam, L. S., Lee, V. W., Lee, K. K. & Li, E. K. Relationship between flare and health-related quality of life in patients with systemic lupus erythematosus. J. Rheumatol. 37, 568\u2013573 (2010).","journal-title":"J. Rheumatol."},{"key":"653_CR227","first-page":"2595","volume":"26","author":"TV Vu","year":"1999","unstructured":"Vu, T. V. & Escalante, A. A comparison of the quality of life of patients with systemic lupus erythematosus with and without endstage renal disease. J. Rheumatol. 26, 2595\u20132601 (1999).","journal-title":"J. Rheumatol."},{"key":"653_CR228","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/hdi.13138","volume":"28","author":"K Doshi","year":"2024","unstructured":"Doshi, K. et al. Health-related quality of life for pediatric patients with end-stage kidney disease: a systematic review and meta-analysis of the pediatric quality of life inventory (PedsQL). Hemodial. Int. 28, 198\u2013215 (2024).","journal-title":"Hemodial. Int."},{"key":"653_CR229","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/0961203317717082","volume":"27","author":"M Jolly","year":"2018","unstructured":"Jolly, M. et al. Disease-specific quality of life in patients with lupus nephritis. Lupus 27, 257\u2013264 (2018).","journal-title":"Lupus"},{"key":"653_CR230","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/acr.22850","volume":"68","author":"K McElhone","year":"2016","unstructured":"McElhone, K. et al. Sensitivity to change and minimal important differences of the LupusQoL in patients with systemic lupus erythematosus. Arthritis Care Res. 68, 1505\u20131513 (2016).","journal-title":"Arthritis Care Res."},{"key":"653_CR231","doi-asserted-by":"publisher","unstructured":"Williams-Hall, R. et al. Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN). Lupus Sci. Med. https:\/\/doi.org\/10.1136\/lupus-2022-000712 (2022).","DOI":"10.1136\/lupus-2022-000712"},{"key":"653_CR232","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae189","author":"PM Carlucci","year":"2024","unstructured":"Carlucci, P. M. et al. Extrarenal symptoms associate with worse quality of life in patients enrolled in the AMP RA\/SLE lupus nephritis network. Rheumatology https:\/\/doi.org\/10.1093\/rheumatology\/keae189 (2024).","journal-title":"Rheumatology"},{"key":"653_CR233","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s10067-024-06909-4","volume":"43","author":"JL Rogers","year":"2024","unstructured":"Rogers, J. L. et al. Evaluation of Type 2 SLE symptoms in patients with a range of lupus nephritis activity. Clin. Rheumatol. 43, 1319\u20131326 (2024).","journal-title":"Clin. Rheumatol."},{"key":"653_CR234","first-page":"1699","volume":"34","author":"C Grootscholten","year":"2007","unstructured":"Grootscholten, C. et al. Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine\/ methylprednisolone in a randomized controlled trial. J. Rheumatol. 34, 1699\u20131707 (2007).","journal-title":"J. Rheumatol."},{"key":"653_CR235","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1191\/0961203306lu2307xx","volume":"15","author":"KC Tse","year":"2006","unstructured":"Tse, K. C., Tang, C. S., Lio, W. I., Lam, M. F. & Chan, T. M. Quality of life comparison between corticosteroid- and-mycofenolate mofetil and corticosteroid- and-oral cyclophosphamide in the treatment of severe lupus nephritis. Lupus 15, 371\u2013379 (2006).","journal-title":"Lupus"},{"key":"653_CR236","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.clim.2016.08.001","volume":"185","author":"S Soliman","year":"2017","unstructured":"Soliman, S. & Mohan, C. Lupus nephritis biomarkers. Clin. Immunol. 185, 10\u201320 (2017).","journal-title":"Clin. Immunol."},{"key":"653_CR237","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1136\/annrheumdis-2012-202784","volume":"73","author":"P Enghard","year":"2014","unstructured":"Enghard, P. et al. Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response. Ann. Rheum. Dis. 73, 277\u2013283 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR238","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/ki.2011.354","volume":"81","author":"X Zhang","year":"2012","unstructured":"Zhang, X. et al. A composite urine biomarker reflects interstitial inflammation in lupus nephritis kidney biopsies. Kidney Int. 81, 401\u2013406 (2012).","journal-title":"Kidney Int."},{"key":"653_CR239","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/art.42023","volume":"74","author":"A Fava","year":"2022","unstructured":"Fava, A. et al. Urine proteomics and renal single-cell transcriptomics implicate interleukin-16 in lupus nephritis. Arthritis Rheumatol. 74, 829\u2013839 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"653_CR240","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.172569","volume":"9","author":"A Fava","year":"2024","unstructured":"Fava, A. et al. Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis. JCI Insight 9, e172569 (2024).","journal-title":"JCI Insight"},{"key":"653_CR241","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000744","volume":"9","author":"A H\u00e4yry","year":"2022","unstructured":"H\u00e4yry, A. et al. Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis. Lupus Sci. Med. 9, e000744 (2022).","journal-title":"Lupus Sci. Med."},{"key":"653_CR242","doi-asserted-by":"publisher","first-page":"885307","DOI":"10.3389\/fimmu.2022.885307","volume":"13","author":"SA Soliman","year":"2022","unstructured":"Soliman, S. A. et al. Urine ALCAM, PF4 and VCAM-1 surpass conventional metrics in identifying nephritis disease activity in childhood-onset systemic lupus erythematosus. Front. Immunol. 13, 885307 (2022).","journal-title":"Front. Immunol."},{"key":"653_CR243","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1093\/rheumatology\/kez528","volume":"59","author":"I Parodis","year":"2020","unstructured":"Parodis, I. et al. ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus. Rheumatology 59, 2237\u20132249 (2020).","journal-title":"Rheumatology"},{"key":"653_CR244","doi-asserted-by":"publisher","DOI":"10.1172\/JCI147334","volume":"132","author":"SA Chalmers","year":"2022","unstructured":"Chalmers, S. A. et al. The CD6\/ALCAM pathway promotes lupus nephritis via T cell-mediated responses. J. Clin. Invest. 132, e147334 (2022).","journal-title":"J. Clin. Invest."},{"key":"653_CR245","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie, R. A. et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 81, 100\u2013107 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR246","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller, F. et al. CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med."},{"key":"653_CR247","doi-asserted-by":"publisher","first-page":"101104","DOI":"10.1016\/j.omtm.2023.08.023","volume":"31","author":"D Nunez","year":"2023","unstructured":"Nunez, D. et al. Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy. Mol. Ther. Methods Clin. Dev. 31, 101104 (2023).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"653_CR248","first-page":"1629","volume":"390","author":"F De Benedetti","year":"2024","unstructured":"De Benedetti, F., Diomedi Camassei, F. & Locatelli, F. CAR T-cell therapy in autoimmune disease. N. Engl. J. Med. 390, 1629 (2024).","journal-title":"N. Engl. J. Med."},{"key":"653_CR249","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","volume":"403","author":"T Krickau","year":"2024","unstructured":"Krickau, T. et al. CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis. Lancet 403, 1627\u20131630 (2024).","journal-title":"Lancet"},{"key":"653_CR250","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.06.2132","author":"P Garantziotis","year":"2025","unstructured":"Garantziotis, P. et al. Differential molecular signatures in response to CD19-CAR T cell therapy compared with conventional pharmacotherapy in systemic lupus erythematosus. Ann. Rheum. Dis. https:\/\/doi.org\/10.1016\/j.ard.2025.06.2132 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR251","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1191\/0961203304lu525oa","volume":"13","author":"D Jayne","year":"2004","unstructured":"Jayne, D. et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 13, 168\u2013176 (2004).","journal-title":"Lupus"},{"key":"653_CR252","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","volume":"81","author":"D Jayne","year":"2022","unstructured":"Jayne, D. et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann. Rheum. Dis. 81, 496\u2013506 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"653_CR253","doi-asserted-by":"publisher","first-page":"ii50","DOI":"10.1093\/ndt\/gfad069","volume":"38","author":"HJ Anders","year":"2023","unstructured":"Anders, H. J. et al. CKD therapy to improve outcomes of immune-mediated glomerular diseases. Nephrol. Dial. Transplant. 38, ii50\u2013ii57 (2023).","journal-title":"Nephrol. Dial. Transplant."},{"key":"653_CR254","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.kint.2016.05.017","volume":"90","author":"HJ Anders","year":"2016","unstructured":"Anders, H. J. & Rovin, B. A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. Kidney Int. 90, 493\u2013501 (2016). This seminal work introduces a pathophysiology-driven framework for diagnosing and managing LN, offering mechanistic insights that inform current and emerging therapeutic strategies.","journal-title":"Kidney Int."}],"container-title":["Nature Reviews Disease Primers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41572-025-00653-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-025-00653-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-025-00653-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T07:03:49Z","timestamp":1758783829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41572-025-00653-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":254,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["653"],"URL":"https:\/\/doi.org\/10.1038\/s41572-025-00653-y","relation":{},"ISSN":["2056-676X"],"issn-type":[{"value":"2056-676X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"20 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.P. has received research funding and\/or honoraria from Amgen, AstraZeneca, Aurinia, BMS, Elli Lilly, Gilead, GSK, Janssen, Novartis, Otsuka and Roche. B.H.R. has received funding from Biogen and consultancy fees from Alexion, Vera, Roche\/Genentech, AstraZeneca, GSK, Kyverna, Artiva, Aurinia, Novartis, Biogen, Sana, Otsuka, Kezar and HiBio. M.G.T. has received research funding and\/or honoraria from Abbvie, BMS, DEMO, GSK, Lilly, Novartis and UCB. H.-J.A. has received funding from Boehringer-Ingelheim and consultancy fees from Novartis, AstraZeneca, Bayer, Boehringer-Ingelheim, Vifor, Otsuka, Roche and Lilly, as well as payments from the European Renal Association for his role as Editor-in-Chief of\n                      Nephrology Dialysis Transplantation\n                      . H.-J.A. is a member of the Western-European Regional board of the International Society of Nephrology (ISN). A.M. serves as a board member and\/or consultant for Roche, BMS, GSK, Kezar, Biogen, Genentech, Novartis and Pfizer. C.M. has received consultancy fees or sponsored research agreement or equity from Boehringer-Ingelheim, Equillium, Progentec Diagnostics and Voyager Therapeutics. C.M. is on the Medical Scientific Advisory Council of the Lupus Foundation of America. C.C.M. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}